46 related articles for article (PubMed ID: 34991998)
1. Neglected geriatric assessment and overtreatment of older patients with pancreatic cancer - Results from a prospective phase IV clinical trial.
Betge J; Schulte N; Belle S; Zhan T; Krammer-Steiner B; Moulin JC; Kleiß M; Lammert F; Wedding U; Räth S; Maenz M; Hegele L; Larcher-Senn J; Jesenofsky R; Ebert MP; Härtel N
J Geriatr Oncol; 2022 Jun; 13(5):662-666. PubMed ID: 34991998
[TBL] [Abstract][Full Text] [Related]
2. A multicenter phase 4 geriatric assessment directed trial to evaluate gemcitabine +/- nab-paclitaxel in elderly pancreatic cancer patients (GrantPax).
Betge J; Chi-Kern J; Schulte N; Belle S; Gutting T; Burgermeister E; Jesenofsky R; Maenz M; Wedding U; Ebert MP; Haertel N
BMC Cancer; 2018 Jul; 18(1):747. PubMed ID: 30021548
[TBL] [Abstract][Full Text] [Related]
3. Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine+nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study.
Yalcin S; Dane F; Oksuzoglu B; Ozdemir NY; Isikdogan A; Ozkan M; Demirag GG; Coskun HS; Karabulut B; Evrensel T; Ustaoglu MA; Ozdemir F; Turna H; Yavuzsen T; Aykan F; Sevinc A; Akbulut H; Yuce D; Hayran M; Kilickap S
BMC Cancer; 2020 Mar; 20(1):259. PubMed ID: 32228512
[TBL] [Abstract][Full Text] [Related]
4. LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study.
Musher BL; Rowinsky EK; Smaglo BG; Abidi W; Othman M; Patel K; Jawaid S; Jing J; Brisco A; Leen AM; Wu M; Sandin LC; Wenthe J; Eriksson E; Ullenhag GJ; Grilley B; Leja-Jarblad J; Hilsenbeck SG; Brenner MK; Loskog ASI
Lancet Oncol; 2024 Apr; 25(4):488-500. PubMed ID: 38547893
[TBL] [Abstract][Full Text] [Related]
5. Quality of life and outcome of patients with metastatic pancreatic cancer receiving first-line chemotherapy with nab-paclitaxel and gemcitabine: Real-life results from the prospective QOLIXANE trial of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer registry.
Al-Batran SE; Hofheinz RD; Reichart A; Pauligk C; Schönherr C; Schlag R; Siegler G; Dörfel S; Koenigsmann M; Zahn MO; Schubert J; Aldaoud A; Höffkes HG; Schulz H; Hahn L; Uhlig J; Blau W; Stauch M; Weniger J; Wolf M; Jacobasch L; Bildat S; Wehmeyer J; Homann N; Trojan J; Waidmann O; Fietz T; Feustel HP; Groschek M; Wierecky J; Waibel K; Mahlmann S; Schwindel U; Peters U; Schuch G; Pink D; Eschenburg H; Wörns MA; Harich HD; von Weikersthal LF; Däßler KU; Behringer DM; Messmann H; Kretzschmar A; Gallmeier E; Forstbauer H; Kunzmann V; Papke J; Büchner-Steudel P; Vehling-Kaiser U; Springfeld C; Vogel A; Ettrich TJ; Schaaf M; Hausen GZ; Götze TO;
Int J Cancer; 2021 Mar; 148(6):1478-1488. PubMed ID: 33038277
[TBL] [Abstract][Full Text] [Related]
6. The GIANT trial (ECOG-ACRIN EA2186) methods paper: A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer - defining a new treatment option for older vulnerable patients.
Dotan E; Catalano P; Lenchik L; Boutin R; Yao X; Marques HS; Ioffe D; Zhen DB; Li D; Wagner LI; Simon MA; Wong TZ; O'Dwyer PJ
J Geriatr Oncol; 2023 Apr; 14(3):101474. PubMed ID: 36963200
[TBL] [Abstract][Full Text] [Related]
7. The Prognostic Utility of a Geriatric Assessment for Patients with Pancreatic Cancer Receiving Gemcitabine-based Chemotherapy: A Prospective Observational Study.
Kitamura H; Nakazawa J; Nagashima F; Andou M; Furuse J
Intern Med; 2023 Jun; 62(11):1573-1580. PubMed ID: 36223928
[TBL] [Abstract][Full Text] [Related]
8. A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01).
Rasmussen LS; Winther SB; Chen IM; Weber B; Ventzel L; Liposits G; Johansen JS; Detlefsen S; Egendal I; Shim S; Christensen S; Pfeiffer P; Ladekarl M
BMC Cancer; 2023 Jun; 23(1):552. PubMed ID: 37328835
[TBL] [Abstract][Full Text] [Related]
9. Comparing the Efficacy and Safety of Gemcitabine plus Nab-Paclitaxel versus Gemcitabine Alone in Older Adults with Unresectable Pancreatic Cancer.
Kobayashi S; Suzuki M; Ueno M; Maruki Y; Okano N; Todaka A; Ozaka M; Tsuji K; Shioji K; Doi K; Kojima Y; Tsumura H; Tanaka K; Higuchi H; Kawabe K; Imaoka H; Yamashita T; Miwa H; Nagano H; Arima S; Hayashi H; Naganuma A; Yamaguchi H; Hisano T; Umemoto K; Ishii S; Nakashima K; Suzuki R; Kitano Y; Misumi T; Furuse J; Ishii H
Oncologist; 2022 Oct; 27(10):e774-e782. PubMed ID: 35946841
[TBL] [Abstract][Full Text] [Related]
10. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer.
Oar A; Lee M; Le H; Wilson K; Aiken C; Chantrill L; Simes J; Nguyen N; Barbour A; Samra J; Sjoquist KM; Moore A; Espinoza D; Gebski V; Yip S; Chu J; Kneebone A; Goldstein D
BMC Cancer; 2021 Aug; 21(1):936. PubMed ID: 34412605
[TBL] [Abstract][Full Text] [Related]
11. A multicenter phase 1/2 study investigating the safety, pharmacokinetics, pharmacodynamics and efficacy of a small molecule antimetabolite, RX-3117, plus nab-paclitaxel in pancreatic adenocarcinoma.
Babiker H; Schlegel PJ; Hicks LG; Bullock AJ; Burhani N; Mahadevan D; Elquza E; Borad MJ; Benaim E; Peterson C; Heaton C; Ocean AJ
Invest New Drugs; 2022 Feb; 40(1):81-90. PubMed ID: 34417914
[TBL] [Abstract][Full Text] [Related]
12. Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group.
Hirata K; Hamamoto Y; Ando M; Imamura CK; Yoshimura K; Yamazaki K; Hironaka S; Muro K
BMC Cancer; 2020 Jun; 20(1):548. PubMed ID: 32532230
[TBL] [Abstract][Full Text] [Related]
13. Low-dose nab-paclitaxel-based combination chemotherapy in heavily pretreated pancreatic cancer patients.
Yang SH; Guo JC; Hsu C; Kuo SH; Tien YW; Cheng AL; Yeh KH
J Formos Med Assoc; 2020 Jan; 119(1 Pt 1):97-105. PubMed ID: 30852003
[TBL] [Abstract][Full Text] [Related]
14. Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial.
Bekaii-Saab T; Okusaka T; Goldstein D; Oh DY; Ueno M; Ioka T; Fang W; Anderson EC; Noel MS; Reni M; Choi HJ; Goldberg JS; Oh SC; Li CP; Tabernero J; Li J; Foos E; Oh C; Van Cutsem E
EClinicalMedicine; 2023 Apr; 58():101897. PubMed ID: 36969338
[TBL] [Abstract][Full Text] [Related]
15. Sequential Geriatric Assessment in Older Patients with Colorectal Cancer during Chemotherapy: Subgroup Analysis of a Prospective, Multicenter Study EpiReal 75.
Li M; Schulte N; Elting F; Winkler EC; Hetjens S; Berger AK; Zschäbitz S; Hofmann J; Hofmann J; Hilbertz L; Kuhn M; Khakzar C; Jesenofsky R; Betge J; Zhan T; Belle S; Ebert MP; Härtel N
Oncol Res Treat; 2022; 45(11):670-680. PubMed ID: 35675788
[TBL] [Abstract][Full Text] [Related]
16. Drug Interactions Causing Warfarin Overdose in a Patient with Pancreatic Cancer: A Case Report.
Moussouni M; Graff V; Couturier F; Herrscher H
Chemotherapy; 2023; 68(2):111-114. PubMed ID: 36446317
[TBL] [Abstract][Full Text] [Related]
17. PD-1 blockade combined with gemcitabine plus nab-paclitaxel is superior to chemotherapy alone in the management of unresectable stage III/IV pancreatic cancer: a retrospective real-world study.
Cheng D; Hu J; Wu X; Wang B; Chen R; Zhao W; Fang C; Ji M
Front Oncol; 2023; 13():1281545. PubMed ID: 37965469
[TBL] [Abstract][Full Text] [Related]
18. The effect of comprehensive geriatric assessment on care received, treatment completion, toxicity, cancer-related and geriatric assessment outcomes, and quality of life for older adults receiving systemic anti-cancer treatment: A systematic review.
Disalvo D; Moth E; Soo WK; Garcia MV; Blinman P; Steer C; Amgarth-Duff I; Power J; Phillips J; Agar M
J Geriatr Oncol; 2023 Nov; 14(8):101585. PubMed ID: 37573197
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of the G8 Geriatric Assessment Tool as a Prognostic Factor in Gemcitabine Plus Nab-paclitaxel Combination Therapy for Elderly Patients with Pancreatic Cancer.
Kadokura M; Mori Y; Takenaka Y; Yoda H; Yasumura T; Tanaka K; Amemiya F
JMA J; 2022 Oct; 5(4):512-519. PubMed ID: 36407075
[TBL] [Abstract][Full Text] [Related]
20. Impact of Geriatric Assessment on the Tolerability of Combination Chemotherapy in Older Patients with Advanced Cancer: A Matched-Pair Analysis.
Stahl MK; Ertl SW; Engelmeyer P; Heuer HC; Christoph DC
Oncol Res Treat; 2023; 46(3):100-105. PubMed ID: 36754037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
